DC4U’s GlycoDCTM targeting technology can be applied to restore tolerance in allergic patients. This can be achieved via induction of regulatory T-cells by glycan-modification of allergens or peptides derived from these allergens. Additionally, dendritic cells (DCs) targeted with the glycan-modified allergens may inhibit established allergen-specific T-cells directly.
We recently obtained strong evidence that certain glycans are involved in tolerance induction. Conjugation of specific inhibitory glycans to antigens target the formulation to DCs that endows them with tolerogenic properties as shown by the induction of regulatory T cell (Treg) induction and inhibition of effector T cell generation. This tolerogenic feature is even maintained under inflammatory conditions. We believe in the potential application of this technology in development of products for food allergy treatment.
Glycan-conjugated disease-specific allergens may be used for effective treatment of different types of food allergies including peanut- and cow’s milk allergy. To exploit the potential for DC4U’s GlycoDCTM targeting technology in the development of anti-allergy products, we offer business and partnering options to life science companies actively involved in allergy research and development.